John Capodanno is a Partner at DGA Group and is based in New York.  He is part of the leadership team for the Health and Life Sciences practice, counseling clients on communicating business strategy, driving valuation, and managing and mitigating issues to provide them with the freedom to operate in a highly regulated and internationally competitive market.  

Mr. Capodanno has built his career advising C-Suites and heads of communications in areas including corporate communications strategy, capital markets, transactions, restructurings, crises, employee engagement and change management.

Mr. Capodanno has a long track record of leading and building programs for some of the world’s largest pharmaceutical and healthcare companies as well as small, innovative life science companies. His experience includes leading an award-winning program for one of the largest healthcare mergers in the past 10 years; serving as an expert witness on behalf of a medical device company as claimant and counter-responder in litigation around the role of communications and best practices for clinical trials; and conceptualizing and implementing communications efforts for the foundation of a Fortune 500 company, which won a top award from GBC Health.  

Prior to joining DGA Group, Mr. Capodanno was President of Financial, Corporate & Capital Markets Communications at Real Chemistry and, before that he was Senior Managing Director and Head of Healthcare & Life Sciences at FTI Consulting.  

Mr. Capodanno holds an M.A. in English literature from Brooklyn College and a B.A. from SUNY Albany.